Niagen Bioscience, Inc. NAGE

Company Overview

Niagen Bioscience, Inc. (NASDAQ: NAGE) is a biotechnology and nutraceutical company focused on healthy aging, cellular metabolism, and nicotinamide adenine dinucleotide (NAD+) science. The company develops and commercializes ingredients, consumer products, and intellectual property related primarily to nicotinamide riboside (NR), a precursor to NAD+, which is involved in cellular energy production and metabolic function. The company operates within the dietary supplements, bioscience, and longevity-focused health sectors, with activities spanning scientific research, ingredient commercialization, and consumer wellness products.

The company’s primary revenue drivers include sales of its patented nicotinamide riboside ingredient branded as Niagen®, direct-to-consumer supplement products marketed under Tru Niagen®, and licensing or business-to-business supply agreements with commercial partners. Niagen Bioscience serves consumers interested in healthy aging, cognitive health, metabolic wellness, and cellular health, while also supplying ingredient solutions to manufacturers and health-product companies. Originally founded in 1999 as ChromaDex Corporation, the company evolved from an analytical standards and ingredient verification business into a bioscience-focused enterprise centered on NAD+ research and commercialization. The company formally rebranded to Niagen Bioscience to align more directly with its flagship ingredient and longevity-science strategy.

Business Operations

Niagen Bioscience generates revenue through a combination of consumer supplement sales, ingredient licensing, and scientific collaborations. Its principal operating activities are centered on Tru Niagen® consumer products and the commercialization of Niagen® as a patented ingredient for use in dietary supplements and functional health products. The company maintains a substantial intellectual property portfolio covering nicotinamide riboside formulations, manufacturing processes, and therapeutic applications. Research and development efforts are supported through clinical studies, scientific partnerships, and collaborations with academic institutions studying NAD+ metabolism and aging-related biology.

Operations extend across both domestic and international markets, with product distribution in North America, Europe, and parts of Asia-Pacific. The company utilizes third-party manufacturing and supply-chain partners while maintaining control over formulation standards, branding, scientific validation, and intellectual property strategy. Niagen Bioscience has historically maintained commercial partnerships with supplement and consumer health companies using Niagen® as an ingredient in branded products. Public filings and investor materials also reference collaborations with universities and medical research institutions investigating applications of NAD+ science in metabolic health, neurodegeneration, and age-associated physiological decline.

Strategic Position & Investments

Niagen Bioscience’s strategic direction centers on expanding the scientific and commercial adoption of NAD+ supplementation and positioning Niagen® as a clinically validated longevity-health ingredient. Growth initiatives include increasing direct-to-consumer subscription sales for Tru Niagen®, expanding international distribution, pursuing additional clinical validation studies, and strengthening intellectual property protections around nicotinamide riboside technologies. The company has consistently emphasized peer-reviewed research and human clinical trials as a competitive differentiator within the broader supplement industry.

The company has also invested in scientific partnerships, biomarker research, and new product formulations tied to healthy aging and cellular resilience. Strategic emphasis has been placed on maintaining exclusivity and patent protections surrounding nicotinamide riboside compounds and related applications. Public disclosures indicate continued investment in emerging longevity and metabolic-health sectors, though some future therapeutic applications remain in early-stage research and are not yet commercially established. Data regarding certain pipeline applications and future medical-use commercialization remains inconclusive based on available public sources.

Geographic Footprint

Niagen Bioscience is headquartered in Los Angeles, California, and operates primarily in the United States while maintaining commercial reach across multiple international regions. The company distributes products through e-commerce channels, retail partnerships, and business-to-business ingredient relationships in North America, Europe, and selected Asia-Pacific markets. International expansion has focused on regions with growing consumer interest in longevity science and premium nutritional supplements.

The company’s ingredient and consumer-product businesses have established a presence in several countries through distribution agreements and regulatory approvals for nicotinamide riboside products. Public filings and corporate materials indicate continued efforts to expand market penetration internationally, particularly in developed health and wellness markets. While the company’s operational footprint is global in distribution scope, most core corporate functions, intellectual property management, and strategic leadership remain concentrated in the United States.

Leadership & Governance

Niagen Bioscience is led by executives with backgrounds in biotechnology, nutrition science, finance, and consumer health commercialization. The company’s leadership strategy has consistently emphasized scientific credibility, clinical validation, intellectual property development, and brand expansion within the healthy-aging category. Governance oversight is provided through its board of directors and executive leadership team, with strategic focus on long-term growth in NAD+ and longevity science markets.

Key executives include:

• Rob Fried – Chief Executive Officer
• Matthew Roberts – Executive Vice President and Chief Scientific Officer
• Ozan Pamir – Chief Financial Officer
• Mark Friedman – General Counsel and Corporate Secretary
• Jared S. Grossman – Senior Vice President of Global Sales

Public statements and investor communications indicate leadership has prioritized evidence-based commercialization, patent defense, consumer subscription growth, and continued scientific investment as central components of the company’s long-term strategic vision.